Ipsen casts doubt on Pfizer’s prostate plan
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
ASCO-GU – picking apart Exelixis’s Contact-02 win
A rare success for Cabometyx sees a survival benefit, but the control regimen raises questions.
